Inipharm

Executive Summary

Inipharm is a clinical-stage biopharmaceutical company developing first-in-class small-molecule therapies for severe liver diseases, with a particular focus on non-alcoholic steatohepatitis (NASH) and other conditions. The company’s lead asset, INI-822, is a potent, oral inhibitor of HSD17B13, a genetically validated target where loss-of-function variants are associated with reduced risk of liver fibrosis and cirrhosis. By targeting this key enzyme, Inipharm aims to slow or halt disease progression across a spectrum of liver disorders. INI-822 is currently in Phase 3 clinical trials, positioning Inipharm as a late-stage player in the liver disease landscape. The company was founded in 1999 and is headquartered in Seattle, Washington, operating as a private entity. Inipharm’s strategic focus on a validated genetic target differentiates its approach in an increasingly competitive NASH market, offering potential for disease-modifying effects with a favorable safety profile.

Upcoming Catalysts (preview)

• Q1 2027Phase 3 top-line data for INI-822 in NASH60% success
• H2 2026Strategic partnership or licensing agreement for INI-822 or platform50% success
• Q3 2026Regulatory update or end-of-phase 2 meeting outcome70% success